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The rate-limiting step of dietary calcium absorption in the intestine requires the brush border calcium entry
channel TRPV6. The TRPV6 gene was completely sequenced in 170 renal calcium stone patients. The fre-
quency of an ancestral TRPV6 haplotype consisting of three non-synonymous polymorphisms (C157R,
M378V, M681T) was significantly higher (P 5 0.039) in calcium stone formers (8.4%; derived 5 502,
ancestral 5 46) compared to non-stone-forming individuals (5.4%; derived 5 645, ancestral 5 37). Mineral
metabolism was investigated on four different calcium regimens: (i) free-choice diet, (ii) low calcium diet,
(iii) fasting and (iv) after a 1 g oral calcium load. When patients homozygous for the derived haplotype
were compared with heterozygous patients, no differences were found with respect to the plasma concen-
trations of 1,25-vitamin D, PTH and calcium, and the urinary excretion of calcium. In one stone-forming
patient, the ancestral haplotype was found to be homozygous. This patient had absorptive hypercalciuria.
We therefore expressed the ancestral protein (157R1378V1681T) in Xenopus oocytes and found a signifi-
cantly enhanced calcium permeability when tested by a 45Ca21 uptake assay (7.11+ 1.93 versus 3.61+
1.01 pmol/min/oocyte for ancestral versus derived haplotype, P < 0.01). These results suggest that the ances-
tral gain-of-function haplotype in TRPV6 plays a role in calcium stone formation in certain forms of absorptive
hypercalciuria.
INTRODUCTION
Kidney stone disease is a major health problem worldwide,
with a lifetime incidence of 10%. Genetic factors appear
to be involved since 40% of these patients have a positive
family history. Idiopathic hypercalciuria is the most common
abnormality observed in calcium (Ca2þ) stone formers (1–3).
It has previously been reported that polymorphisms in the
vitamin D receptor (VDR) gene are associated with a specific
form of absorptive hypercalciuria, causing hyper-activation of
intestinal Ca2þ absorption (4). Moreover, spontaneous stone-
forming rats [genetic hypercalciuria stone-forming (GHS)
rats] have higher levels of VDR protein in the small intestine
compared to wild-type rats (5). Other reports suggested that
Ca2þ-sensing receptor (CaR) polymorphisms are involved in
hypercalciuria without kidney stones (6). These findings indi-
cate that several genes contribute to hypercalciuria. Interest-
ingly, there is no report thus far indicating an association
between hypercalciuria with Ca2þ stone formation and
genetic variations of the genes responsible for epithelial
Ca2þ transport, which could directly affect urine Ca2þ levels.
The intestinal and renal epithelial Ca2þ transport mechan-
isms are comprised of three steps: (i) apical Ca2þ entry via
TRPV-calcium channels (transient receptor potential channels,
subtype V), which is likely to be a rate-limiting step of trans-
epithelial calcium transport; (ii) binding of Ca2þ to calbindin
D which serves as an intracellular Ca2þ buffer, and; (iii) baso-
lateral calcium exit via the plasma membrane Ca2þ pump and/
or the Naþ/Ca2þ exchanger (7,8). Steps 1 and 2 are induced by
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1,25-dihydroxyvitamin D, the active form of vitamin D. The
key molecules for the apical Ca2þ entry, TRPV5 and
TRPV6, were previously identified by expression cloning
from the kidney and small intestine, respectively (9,10).
They are epithelial Ca2þ-selective channels with six trans-
membrane domains and a pore region. Trpv5 knockout mice
exhibited renal leak hypercalciuria with increased intestinal
Ca2þ absorption due to a compensatory upregulation of
Trpv6 (11). In humans however, no phenotype–genotype
relationship between TRPV5 polymorphisms and hypercal-
ciuria has been observed so far (12), possibly due to this com-
pensation. On the other hand, Trpv6 knockout mice exhibited
decreased intestinal Ca2þ absorption without obvious compen-
sation by Trpv5 in the intestine, resulting in secondary hyper-
parathyroidism (13).
In this study, we investigated the coding region of the
TRPV6 gene in 170 Swiss Ca2þ stone formers. We found a
haplotype containing three non-synonymous polymorphisms.
This haplotype has already been described in a recent
genetic study where a positive selection during human evol-
ution was suggested (14). Our functional analysis of this hap-
lotype indicates that it produces a gain-of-function channel,
suggesting that the ancestral haplotype causes hyper-activation
of intestinal Ca2þ absorption, which in turn leads to absorptive
hypercalciuria.
RESULTS
Identification of polymorphisms in Ca21
stone-forming patients
We investigated polymorphisms in 170 Ca2þ stone-forming
patients by direct PCR sequencing of the coding region of
the TRPV6 gene (primer information is available in Sup-
plementary Material, Table S1). Three major non-synonymous
polymorphisms were identified (C157RþM378VþM681T;
Table 1 and Fig. 1A), as well as several low incidence, non-
synonymous polymorphisms (R138CþT269M, L259Q and
A566P; Fig. 1B) and various synonymous polymorphisms
(I283I, L292L, P312P, T360T, N464N, T601T, G626G and
N694N; Table 1 and Supplementary Material, Table S2).
Interestingly, 25 patients had all of the above listed three non-
synonymous polymorphisms, suggesting that these poly-
morphisms represent a set of alleles of a specific haplotype.
We therefore focused on this ancestral haplotype, which
includes the three non-synonymous polymorphisms
(C157RþM378VþM681T), for further analysis.
Clinical data
Table 2 shows the basal characteristics and clinical data of
derived (homozygous for the new haplotype), heterozygous
(new/ancestral haplotype) and homozygous (ancestral haplo-
type) patients. Although there appears to be no difference
between phenotypes based on the parameters shown in
Table 2, the homozygous patient had more stone episodes (.5).
The Ca2þ homeostasis of 170 calcium stone-forming
patients was studied on a self-chosen (random) diet, followed
by 1 week of a low-Ca2þ diet, or after a 1 g oral Ca2þ load at
the end of a 12 h fasting period (Table 3). When derived and
heterozygous patients were compared, no differences were
found with respect to plasma 1,25-dihydroxyvitamin D, PTH
and Ca2þ (Table 3). Urinary Ca2þ excretion was also not
affected under the above-mentioned dietary conditions
(Table 3). The homozygous patient had a 3-fold higher Ca2þ
excretion rate (1.32 mmol/mmol creatinine) after a 1 g oral
Ca2þ load compared to derived and heterozygous patients
(0.47+0.27, 0.47+0.28 mmol/mmol creatinine, respectively)
(Table 3). The plasma PTH level was lower (24 pg/ml) in the
homozygous patient compared to derived and heterozygous
patients (43+ 22, 42+ 12 pg/ml, respectively). With free-
choice and low Ca2þ diets, the Ca2þ excretion was 2-fold
higher in the homozygous patient. This indicates that the
patient had hypercalciuria under normal nutritional conditions.
No differences in bone mineral density were found between
groups (Table 3).
In the cohort of 170 Ca2þ stone formers, the frequency of the
ancestral haplotype was higher [7.6% (derived ¼ 314;
ancestral ¼ 26)] compared to 341 non-stone formers [5.4%
(derived ¼ 645, ancestral ¼ 37] (Table 4). Similarly, the fre-
quency of the ancestral haplotype was higher in 104 stone
formers not investigated by the various calcium regimens
(Table 4). The prevalence of the ancestral haplotype in stone-
forming patients when compared to non-stone-forming patients
(Table 4) was statistically significant (x2 test P ¼ 0.039).
Data of three patients with the four non-synonymous poly-
morphisms (R138CþT269M, L259Q and A566P) are shown
in Supplementary Material, Table S2. These patients were
not included in the clinical-data analysis.
Functional analysis of TRPV6 polymorphisms
To investigate the functional significance of the three non-
synonymous polymorphisms (157Rþ378Vþ681T), 45Ca2þ
transport assays were performed in Xenopus oocytes expres-
sing the corresponding construct. The results indicated that
Ca2þ uptake activity was higher in the ancestral TRPV6
when compared with derived TRPV6 (n ¼ 5, P , 0.01,
Fig. 1C). To estimate Ca2þ transport activity in heterozygous
Table 1. SNPs in the coding region of TRPV6
Nucleotide Amino acid AA exchange n Comment
Exon 4 c415t R138C Arg f Cys 1 New
t471c C157R Cys f Arg 26 rs4987657a
Exon 7 t776a L259Q Leu f Gln 1 New
c806t T269M Thr f Met 1 New
c849t I283I 2 New
g876a L292L 1 New
Exon 8 g936a P312P 1 New
g1080a T360T 26 rs4987665a
Exon 9 a1132g M378V Met f Val 26 rs4987667a
Exon 11 c1392t N464N 21 rs4987704
Exon 13 g1696c A566P Ala f Pro 1 New
Exon 14 g1803a T601T 5 rs4987678
a1878g G626G 26 rs4987679a
Exon 15 t2042c M681T Met f Thr 27 rs4987682a
t2082c N694N 11 rs4987683
n, number of SNPs found in patient cohort.
aSNPs belonging to the ancestral haplotype.
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patients, both derived and ancestral TRPV6 were co-injected
into oocytes. The results showed intermediate activity for
the combination of derived and ancestral TRPV6 (Fig. 1C).
While the 157Rþ681T construct did not significantly increase
Ca2þ transport activity (P ¼ 0.67), the single extracellular
polymorphism (378V) significantly increased Ca2þ transport
activity (n ¼ 4, P, 0.03, Fig. 1D), suggesting that 378V
mainly contributes to the increase in Ca2þ transport activity
of TRPV6.
DISCUSSION
In the present study, we found a haplotype consisting of three
non-synonymous polymorphisms (C157R, M378V and
M681T) in the TRPV6 gene in Ca2þ stone patients
(Table 1). The frequency of the ancestral haplotype
(RþVþT) was higher in Ca2þ stone formers (8.4%) when
compared to a cohort of non-stone formers (5.4%). This
suggests that the ancestral haplotype is a risk factor for
Ca2þ stone formation (Table 3).
Although there was no difference in the phenotypes
between heterozygous (CRþMVþMT) and derived (CCþ
MMþMM) patients, one ancestral patient was found who
Figure 1. Functional analysis of the TRPV6 polymorphisms from Ca2þ stone
patients. (A) Localization of three major non-synonymous TRPV6 polymorph-
isms in the TRPV6 protein. These three polymorphisms (C157R, M378V and
M681T) were on the same allele/haplotype. (B) Two less frequent polymorph-
isms (R138C and T269M) were found in the same patient (grey squares).
L259Q (black square) and A566P (white square) were low incidence single
mutations/polymorphisms. (C) 45Ca2þ uptake analysis in derived
(CþMþM) or the ancestral (RþVþT) TRPV6 in Xenopus oocytes. The
uptake of the ancestral TRPV6 was significantly higher (7.11+1.93 pmol/
min/oocyte, n ¼ 5) compared to derived TRPV6 (3.61+1.01 pmol/min/
oocyte, n ¼ 5). The co-expression of derived and ancestral TRPV6 resulted
in an intermediate transport activity (n ¼ 8), P , 0.01. (D) 45Ca2þ uptake
analysis with TRPV6s (derived TRPV6, 378V and 157Rþ681T). The 378V
also significantly increased this activity (n ¼ 4), P , 0.03.
Table 2. Baseline characteristics and clinical data
CCþMMþMM
(n ¼ 142)
CRþMVþMT
(n ¼ 24)
RRþVVþTT
(n ¼ 1)
Male/female 111/31 17/7 1/0
Age (years) 44.3+12.7 45.6+16.0 45
Height (cm) 171+13.1 173+9 165
Weight (kg) 77.6+16.8 74.5+15.8 71
BMI (kg/m2) 27.1+13.0 24.7+4.2 26.1
Family history of
stones, n
51 10 No
Stone episodes per
patient, n
2.9+1.4 3.1+1.4 .5
Stone type, n
Calcium-oxalate 67 11 1
Calcium-phosphate 5
Nephrocalcinosis 1
Radio-opaque
concrement
69 13
Table 3. Clinical data
CCþMMþMM
(n ¼ 142)
CRþMVþMT
(n ¼ 24)
RRþVVþTT
(n ¼ 1)
Plasma parameters
Free-choice diet
Ionized calcium
(mmol/l)
1.23+0.05 1.22+0.03 1.22
Phosphate (mmol/l) 1.06+0.18 1.07+0.16 1.21
PTH (pg/ml) 43+22 42+12 24
1,25-vitamin D
(pmol/ml)
123+44 122+59 Missing
Low calcium diet
Ionized calcium
(mmol/l)
1.20+0.04 1.19+0.03 1.19
Phosphate (mmol/l) 0.95+0.17 0.97+0.16 1.03
PTH (pg/ml) 45+18 44+13 27
1,25-vitamin D
(pmol/ml)
146+48 148+65 188
Calciuria at/after
Free-choice diet
(mmol/day)
6.8+3.7 6.9+2.7 12.8
Low calcium diet
(mmol/day)
4.0+2.5 4.0+2.0 8.2
Fasting, mmol/mmol
creatinine
0.21+0.14 0.18+0.10 0.31
Calcium load, mmol/
mmol creatinine
0.47+0.27 0.47+0.28 1.32
DEXA, z-score
Lumbar spine 0.01+0.94 0.26+1.06 0.2
Femoral neck 0.32+1.03 0.37+0.94 0.5
Tibia diaphysis 0.61+1.12 0.48+1.03 1
Tibia epiphysis 20.25+0.96 20.23+0.94 20.4
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likely exhibited absorptive hypercalciuria. Indeed, when
ancestral TRPV6 was expressed in Xenopus oocytes, 45Ca2þ
uptake activity was significantly higher compared to derived
TRPV6 (Fig. 1C). This result suggests that the ancestral hap-
lotype can increase intestinal Ca2þ absorption, resulting in
absorptive hypercalciuria. However, in this study, there is
thus far only one homozygous patient who exhibited absorp-
tive hypercalciuria with kidney stones. In order to evaluate
the phenotype–genotype relationship in more detail,
additional homozygous patients with this haplotype need to
be identified and analyzed. To determine whether the increase
in Ca2þ transport activity is related to increased TRPV6 func-
tion, increased surface expression of TRPV6 or decreased
protein degradation will be the subject of future investigations.
To address the effect of heterozygosity with respect to this
haplotype, derived and ancestral TRPV6 were co-expressed
into the same oocyte and 45Ca2þ uptake was measured
(Fig. 1C). The total 45Ca2þ activity appeared to be the sum
of the derived and ancestral TRPV6 activities, suggesting
that the function of these channels was not affected by
co-expression. It is generally assumed that four TRPV6 sub-
units form one channel pore (20). However, our results
suggest that ancestral TRPV6 does not increase the activity
of derived TRPV6 by forming heteromeric channels. This
seems reasonable because there was no dominant effect of
the ancestral haplotype in the Ca2þ stone patients (i.e. there
was no difference in the phenotypes between derived and het-
erozygotes; see Table 2). Nevertheless, it is tempting to specu-
late that the heterozygous haplotype is still significant for the
Ca2þ stone phenotypes. A combination of this haplotype with
polymorphisms in other genes affecting Ca2þ-transport (i.e.
TRPV5; ref. 21) may enhance the risk of stone formations
because this disease is known to be a polygenic disease (1).
During the course of our study, the same ancestral haplo-
type (C157RþM378VþM681T) was found in a whole
genome screening effort, and was reported to represent a posi-
tive selection in human evolution (14,22). In these reports, the
derived haplotype accelerated TRPV6 protein evolution only
in individuals of non-Southern African descent, suggesting
that TRPV6 protein experienced geographically restricted
selection pressure. The investigators hypothesized that this
selection was caused either by a pathogen affecting the func-
tion of TRPV6-expressing B-cells or by the agricultural revo-
lution involving the domestication of milk-producing animals
10 000 years ago. Too much Ca2þ from milk might be a
strong selection pressure because it could cause absorptive
hypercalciuria and urinary Ca2þ stones. Another possibility
is that selection pressure is closely correlated with skin-color
change and 1,25-dihydroxyvitamin D production (23,24).
After moving from Africa to Europe, dark-skin individuals
might need more ultraviolet radiation to produce
1,25-dihydroxyvitamin D. Even now, vitamin D deficiency
is a common problem in individuals with darker skin pigmen-
tation living in northern countries (25). Under this selection
pressure, skin-color changes may have occurred by evolving
several genes involved in pigmentation (i.e. tyrosinase,
MC1R, SLC24A5 and SLC45A2) (26–28). Individuals with
lighter skin pigmentation might then have produced too
much 1,25-dihydroxyvitamin D, resulting in an increased
intestinal Ca2þ absorption. Thus, to reduce the risk of absorp-
tive hypercalciuria with kidney stones, the derived haplotype
would have spread only among individuals with lighter skin
pigmentation.
MATERIALS AND METHODS
Patients and clinical evaluation protocol
All patients (n ¼ 170, no African individuals, Table 3) were
seen for an outpatient metabolic work-up in our renal stone
clinic between March 2004 and March 2007. Inclusion criteria
were as follows: (i) age 18 plus of either gender, (ii) passage of
at least one calcium-containing kidney stone as defined either
by stone analysis or by the presence of opaque material on
conventional radiograph or computed tomography in the
absence of cystinuria. Exclusion criteria were: (i) an estab-
lished cause of calcium stone formation, such as primary
hyperparathyroidism, overt distal renal tubular acidosis, sar-
coidosis, excessive vitamin D intake, hypercalciuria due to
hypercalcemia (immobilization or malignancy) and primary
or enteric hyperoxaluria (patients with inflammatory bowel
disease and short bowel syndrome were excluded), (ii) creati-
nine clearance less than 60 ml/min as calculated from the
serum and urinary creatinine of two 24 h urine collections
and (iii) urinary tract infection. Patients were asked to stop
calcium supplements or any drug that could affect the meta-
bolism of calcium during the evaluation. All patients gave
their consent for their participation and the protocol was
approved by the institutional review board of the University
Hospital Bern.
All patients underwent a three visit mineral metabolism
work-up including a dual energy x-ray absorptiometry
(DEXA). A routine clinical assessment was performed, includ-
ing a physical examination and history. Mineral metabolism
was investigated on four different calcium regimens according
to a protocol first established by Pak et al. (15,16): (i) free-
choice diet, (ii) low-calcium diet, (iii) fasting and (iv) after a
1 g oral calcium load.
In the 24-hour urines, calcium and creatinine were measured
by standard laboratory techniques with an automated analyzer.
Phosphate, calcium and creatinine in the blood were assessed
by standard laboratory methods. Intact parathyroid hormone
was measured by an enzyme-immunoassay (Roche Modular
E170), as was 1,25-vitamin D (Immundiagnostik AG).
Table 4. Prevalence of the ancestral (RVT-) haplotype in stone-forming and
non-stone-forming cohorts
Number of
subjects
CMM
haplotype
RVT
haplotype
Stone formers with metabolic
workup
170 314 (92.4%) 26 (7.6%)
Stone formers without
metabolic workup
104 188 (90.4%) 20 (9.6%)
Total stone formers 274 502 (91.6%) 46 (8.4%)
Hypertensive 180 342 (95.0%) 18 (5.0%)
Healthy 161 303 (94.1%) 19 (5.9%)
Total non-stone formers 341 645 (94.6%) 37 (5.4%)
P ¼ 0.039 (x2 test).
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Hypercalciuria was defined as either fasting or absorptive.
Fasting hypercalciuria was defined as an elevated fasting
urinary calcium-to-creatinine ratio exceeding 0.31 mmol/
mmol (0.11 mg/mg) in the 2 h urine sample. Absorptive
hypercalciuria was defined as a urinary calcium-to-creatinine
ratio of at least 0.56 mmol/mmol (0.20, mg/mg) in the 4 h
urine sample after the oral intake of 1 g calcium (17). Osteo-
densitometry was performed by dual-energy X-ray absorptio-
metry at the second to fourth lumbar vertebra (DXA,
Hologicw scanner QDR 1000 W).
To evaluate the ancestral haplotype in different patient
cohorts, exon 3 was sequenced as a screening procedure in
104 additional stone-forming patients not previously investi-
gated by applying four different calcium regimens, and also
in 180 hypertensive patients and 161 non-hypertensive,
healthy control subjects without a stone history (Table 3).
Complete clinical data sets were not available from these
patients.
Identification of TRPV6 polymorphisms. Genomic DNA was
extracted from blood using QIAamp DNA Mini kit
(Qiagen). For TRPV6 genomic analysis, primers for polymer-
ase chain reactions (PCR) covering all coding regions of the
exons and exon-intron boundaries were designed as listed in
Supplementary Material, Table S1. PCR was performed
using the AmpliTaq Gold system (Applied Biosystems) with
400 pmol of forward and reverse primers and 50 ng of
genomic DNA. The condition for the PCR reactions was as
follows: 35 cycles of denaturizing (948C for 30 s), annealing
[518C (exon 9, 10), 52.58C (exon 11, 12), 53.58C (exon 7,
8), 54.58C (exon 4), 55.58C (exon1, 14), 57.58C (exon 2, 3,
5, 6, 13, 15)] for 30 s, and extension (728C for 1 min). After
the final step at 728C for 7 min, the fragment was confirmed
by agarose gel electrophoresis as a single band. The sequence
of this fragment was determined by ABI 3730XL Genetic
Analyzer (Applied Biosystems) using Big Dye terminator
cycle sequencing. When a polymorphism was detected, the
sequence was read from both the forward and the reverse
side. When the reference sequence (NCBI accession
AY225461.2) of TRPV6 was detected, no additional reverse
sequencing was performed.
Heterologous expression of human TRPV6 in Xenopus
oocytes. All animal experiments were performed according
to the Federal Guidelines of Switzerland. The oocyte
expression vector containing human wild-type TRPV6
cDNA [Af365927; ref. 18] was constructed by NotI/ XhoI
fragment of TRPV6 pBluescript. The constructs (derived
TRPV6, 378V, 157Rþ681T and ancestral TRPV6) were gen-
erated using the QuikChange Multi site-directed mutagenesis
kit (Stratagene), according to the manufacturer’s instruction.
A cRNA was synthesized in vitro by the mMessage mMachine
kit (Ambion) with a linearized vector and SP6 RNA poly-
merase. For oocyte preparation, an ovary was isolated from
Xenopus laevis under 2-aminoethyl benzoate treatment, and
then incubated with collagenase A (Roche). The isolated
oocytes were then incubated overnight at 178C with modified
Barths’ solution (19). Oocytes were injected with 25 ng of
cRNA and incubated at 178C for 2 days before functional
analysis.
Calcium-45 uptake assays. Oocytes were injected with 50 nl
of 50 mM EGTA, 30 min before uptake assay. Calcium
uptake assays were performed with standard uptake solution
(100 mM NaCl, 2 mM KCl, 1.9 mM MgCl2, 0.2 mM CaCl2,
4mCi.ml21 45Ca; Amersham). After incubation for 20 min,
the oocytes were rinsed with the uptake solution and solubil-
ized with 5% SDS. The 45Ca content was analyzed by liquid
scintillation counting.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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